Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein  |  Issue: June 2017  |  June 14, 2017

Dr. Poddar also cites both generic hydroxychloroquine and colchicine, which sells for an average retail price of $162.65 for 30 capsules according to GoodRx.com, as concerns for his patients. “Despite the fact it’s generic, every patient’s insurance is different, and some of my patients may pay $200 for a month’s supply of colchicine. Sometimes, the drug companies give coupons to offset the cost, but some pharmacies won’t accept them. So patients may just go without their drug,” he says. “High uric acid levels can have cardiovascular manifestations, so there are long-term ramifications, not just one joint problem. You can’t just tell these patients to tough it out. It’s not just their joints. These are systemic diseases.”

In his Kingsport, Tenn., rheumatology clinic, Christopher Morris, MD, also cites both colchicine and hydroxychloroquine as “outlandishly expensive, and most of our lupus patients are on generic Plaquenil,” he says. “If they only price a generic a few dollars less than the brand-name drug, there’s really no savings.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients may not understand how their drug coverage on Medicare supplemental plans work when they purchase these policies, says Dr. Morris. They may struggle to pay 20% of the cost of a year’s supply of a drug that costs $25,000. His practice must now devote one full-time staff person just to deal with prior authorizations and insurance company negotiations, he says.

“High-deductible plans may make patients reach a certain level of money spent before they cover the drugs. These patients may have to shell out several thousand dollars before their insurance kicks in,” says Dr. Morris.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Copays Add Up Quickly

Rheumatology health professionals also hear their patients express concerns about high insurance copays adding up quickly for physical therapy and other integrative treatments, says Christine Stamatos, DNP, ANP-C, director of the Fibromyalgia Wellness Center at Northwell Health in Babylon, N.Y.

“I have patients who have to pay $50 for each physical therapy session,” Dr. Stamatos says. “Some patients have insurance policies with a lower premium each month, but very high deductibles, so they may go without their therapy, and this is care that we know is so effective. So it’s frustrating and scary.”

In the rheumatology clinic at the University of Kentucky in Lexington, Associate Professor Elizabeth Salt, PhD, also observes patients delaying care due to higher out-of-pocket costs. “We see decreased healthcare utilization at the beginning of the year when deductibles have not been met, and an increase at the end of the year, trying to get in treatments before the year ends. I see delays in necessary procedures due to cost and patients unable to afford medications due to increased cost,” she says.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Practice Support Tagged with:BiologicsBiosimilarsCompliancecostsdruggenericHealthcareMedicationpatient careRheumatic DiseaserheumatologistTreatment

Related Articles

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

    March 1, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences